Further to intimation dated 29th October, 2025 Caplin Point Laboratories has informed that the Board of Directors, at its meeting held today i.e. 5th November 2025, has approved the following: 1. Approved the Un-audited standalone and consolidated financial results and the Limited Review Report (Annexure-1) of the Company as per Indian Accounting Standards for the quarter and half year ended 30th September, 2025. They also enclosed a Press Release issued by the Company (Annexure 2) and an investor presentation in this regard (Annexure 3). 2. Approved the Appointment of Ashok Partheeban (DIN: 02507261) as an Additional Director and Vice-Chairman of the Company with effect from 5th November 2025 and whose term is liable to retirement by rotation, subject to the approval of shareholders; etc.
The above information is a part of company’s filings submitted to BSE.
